P-61 Polychemotherapy including topotecan combined with twice-daily accelerated radiotherapy in small cell lung cancer (SCLC). Preliminary data from a phase II trial

MLA

Torben Palshof, et al. “P-61 Polychemotherapy Including Topotecan Combined with Twice-Daily Accelerated Radiotherapy in Small Cell Lung Cancer (SCLC). Preliminary Data from a Phase II Trial.” Lung Cancer, vol. 41, Aug. 2003, p. S106. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d724731f51551c2da79341c2ee2fee6f&authtype=sso&custid=ns315887.

APA

Torben Palshof, Seppo W. Langer, Brita Bjerregaard, Ulrik Lassen, Peter Buhl Jensen, & Morten Sorensen. (2003). P-61 Polychemotherapy including topotecan combined with twice-daily accelerated radiotherapy in small cell lung cancer (SCLC). Preliminary data from a phase II trial. Lung Cancer, 41, S106.

Chicago

Torben Palshof, Seppo W. Langer, Brita Bjerregaard, Ulrik Lassen, Peter Buhl Jensen, and Morten Sorensen. 2003. “P-61 Polychemotherapy Including Topotecan Combined with Twice-Daily Accelerated Radiotherapy in Small Cell Lung Cancer (SCLC). Preliminary Data from a Phase II Trial.” Lung Cancer 41 (August): S106. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........d724731f51551c2da79341c2ee2fee6f&authtype=sso&custid=ns315887.